reports
Akari Therapeutics Plc: 2 directors
Two Directors at Akari Therapeutics Plc bought 43,600,000 shares at 0.001USD. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...
AKARI THERAPEUTICS 96 HOUR DEADLINE ALERT: Approximately 96 Hours Rema...
NEW ORLEANS--(BUSINESS WIRE)-- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until July 11, 2017 to file lead plaintiff applications in a securities class action lawsuit against Akari Therapeutics, Plc (NasdaqCM: AKTX). Investor losses must relate to purchases of the Company’s securities between March 30, 2017 and May 11, 2017. This action is pending in the United States District Court for the Southern ...
AKARI LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages I...
NEW YORK--(BUSINESS WIRE)-- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Akari Therapeutics, Plc (“Akari” or the “Company”) (NASDAQ:AKTX) of the July 11, 2017 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Akari American Depository Receipts (“ADRs”) between March 30, 2017 and May 11, 2017 and would like to discuss your legal rights, click here: www.faruqilaw.com/AKTX. There is no co...
AKARI LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages I...
NEW YORK--(BUSINESS WIRE)-- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Akari Therapeutics, Plc (“Akari” or the “Company”) (NASDAQ:AKTX) of the July 11, 2017 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Akari American Depository Receipts (“ADRs”) between March 30, 2017 and May 11, 2017 and would like to discuss your legal rights, click here: www.faruqilaw.com/AKTX. There is no co...
AKARI THERAPEUTICS SHAREHOLDER ALERT by Former Louisiana Attorney Gene...
NEW ORLEANS--(BUSINESS WIRE)-- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 11, 2017 to file lead plaintiff applications in a securities class action lawsuit against Akari Therapeutics, Plc (NasdaqCM: AKTX), if they purchased the Company’s securities between March 30, 2017, and May 11, 2017, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York. ...
Akari Therapeutics Announces Resignation of CEO
NEW YORK & LONDON--(BUSINESS WIRE)-- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, today announced the resignation of Gur Roshwalb, the Company’s Chief Executive Officer, and correction to fifth patient data in the Company’s press release issued on April 24, 2017 (the “Release”). As previously reported by the Company, its Board of Directors established an ad hoc special committee of the Board to review the involvement, if any, of Company personnel with the report issued by ...
IMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of ...
LOS ANGELES--(BUSINESS WIRE)-- Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Akari Therapeutics, Plc (“Akari” or the “Company”) (Nasdaq: AKTX) concerning possible violations of federal securities laws. To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or by email at [email protected]. On April 26, 2017, Edison Research Ltd. issued a report on Akari called “Akari’s Coversin matches Soliris ...
IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class...
IRVINE, Calif.--(BUSINESS WIRE)-- Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Akari Therapeutics, Plc (“Akari” or the “Company”) (Nasdaq: AKTX). Investors who purchased or otherwise acquired shares between March 30, 2017 and May 11, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the July 11, 2017 lead plaintiff motion deadline. If you purchased Akari shares during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang LLP, 181...
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Acti...
NEW YORK--(BUSINESS WIRE)-- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Akari Therapeutics, Plc securities (NASDAQ: AKTX) from March 30, 2017 through May 11, 2017, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Akari Therapeutics investors under the federal securities laws. To join the Akari Therapeutics class action, go to http://www.rosenlegal.com/cases-1127.html or call Phillip Kim, Esq. or Kevin Chan, Esq....
INVESTOR ALERT: Goldberg Law PC Announces the Filing of a Securities C...
LOS ANGELES--(BUSINESS WIRE)-- Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Akari Therapeutics, Plc (“Akari” or the “Company”) (Nasdaq: AKTX) for violations of §10(b) and §20(a) of the Securities Exchange Act of 1934 and U.S. Securities and Exchange Commission Rule 10b-5 promulgated thereunder. Investors who purchased the Company’s shares between March 30, 2017 and May 11, 2017 inclusive (the “Class Period”), are encouraged to contact the firm be...
AKARI INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Su...
NEW YORK--(BUSINESS WIRE)-- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Akari Therapeutics, Plc (“Akari” or the “Company”) (NASDAQ:AKTX). The investigation focuses on whether the Company and its executives violated federal securities laws. Specifically, on May 11, 2017, Akari filed a Form 6-K with the Securities and Exchange Commission announcing that Akari has established an ad hoc special committee to review the involvement of Company personnel regarding a rep...
Glancy Prongay & Murray LLP Commences Investigation on Behalf of Akari...
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Akari Therapeutics, Plc (“Akari” or the “Company”) (NASDAQ: AKTX) investors concerning the Company and its officers’ possible violations of federal securities laws. To obtain information or aid in the investigation, please visit the Akari investigation page on our website at www.glancylaw.com/case/akari-therapeutics-plc. On May 11, 2017, the Company announced that its CEO, Dr. Gur Roshwalb, was placed on administr...
INVESTOR ALERT: Investigation of Akari Therapeutics Announced by Holz...
ATLANTA--(BUSINESS WIRE)-- Holzer & Holzer, LLC is investigating whether certain statements issued by Akari Therapeutics, Plc (“Akari Therapeutics” or the “Company”) (NASDAQ: AKTX) complied with federal securities laws. On May 11, 2017, Akari Therapeutics announced that its Chief Executive Officer, Dr. Gur Roshwalb, had been placed on administrative leave while the Company’s Board of Directors reviewed whether he had any involvement in the release of a recently withdrawn Edison Investment Research report. The price of Akari Therapeuti...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of...
NEW YORK--(BUSINESS WIRE)-- Levi & Korsinsky announces it has commenced an investigation of Akari Therapeutics (NASDAQ: AKTX) concerning possible violations of federal securities laws. On April 26, 2017, Edison Research Ltd. issued a report on Akari called “Akari’s Coversin matches Soliris in Phase II.” The following day, it was announced the report had been withdraw due to “material inaccuracies.” Then on May 11, 2017, the Company announced that CEO Dr. Gur Roshwalb has been placed on administrative leave while the Board of ...
- Neil Shah
Suspension of Coverage
Whilst following Edison’s normal publication process, which includes a review of a note by a supervisory analyst and a fact checking of the document by the issuer, it has come to light that there were material errors in the last note Edison published on Akari Therapeutics. Edison has withdrawn the last note from circulation and is conducting a review of the coverage. Whilst we undertake this review, the Director of Research has taken the decision to suspend coverage of Akari Therapeutics. Accord...
- Maxim Jacobs
Coversin matches Soliris in Phase II
Akari held an R&D day on 24 April 2017, at which it announced the interim results from the Phase II clinical trial of Coversin for paroxysmal nocturnal hemoglobinuria (PNH). The four patients who completed the study met the primary endpoint of hemolysis within 1.8x the upper limit of normal (ULN), with the average at 1.5x ULN, which is considered optimal control similar to Soliris. Additionally, it announced the initiation of an atypical hemolytic uremic syndrome (aHUS) Phase II in Q217 and two ...
- Maxim Jacobs
ASH data highlight Coversin’s unique properties
Akari provided an update at the American Society of Hematology (ASH) meeting on the Soliris-resistant patient who has now been well controlled with Coversin for nine months. New data were released supporting a once-daily dosing, with complete inhibition of hemolysis with 22.5mg and 30mg per day. The company also provided guidance on new indications either by leveraging Coversin’s leukotriene B4 activity, or its ease of derivatization into new longer lasting and targeted versions. Results from th...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.